Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
IN |
|
A
|
Agillic A/S
CSE:AGILC
|
DK |
|
Aeon Fantasy Co Ltd
TSE:4343
|
JP |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
US |
|
Vodacom Group Ltd
OTC:VDMCY
|
ZA |
|
SNT Dynamics Co Ltd
KRX:003570
|
KR |
|
V
|
VEON Ltd
AEX:VEON
|
NL |
|
A
|
Avi Ltd
JSE:AVI
|
ZA |
|
iDreamSky Technology Holdings Ltd
HKEX:1119
|
CN |
|
Build-A-Bear Workshop Inc
NYSE:BBW
|
US |
Wall Street
Price Targets
AKUMS Price Targets Summary
Akums Drugs and Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for AKUMS is 686.8 INR with a low forecast of 616.1 INR and a high forecast of 766.5 INR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is AKUMS's stock price target?
Price Target
686.8
INR
According to Wall Street analysts, the average 1-year price target for AKUMS is 686.8 INR with a low forecast of 616.1 INR and a high forecast of 766.5 INR.
What is Akums Drugs and Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
12%
For the last 1 year the compound annual growth rate for Akums Drugs and Pharmaceuticals Ltd's revenue is -1%. The projected CAGR for the next 3 years is 12%.
What is Akums Drugs and Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
29%
For the last 1 year the compound annual growth rate for Akums Drugs and Pharmaceuticals Ltd's operating income is -13%. The projected CAGR for the next 3 years is 29%.
What is Akums Drugs and Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
14%
The compound annual growth rate of Akums Drugs and Pharmaceuticals Ltd's net income for the next 3 years is 14%.